Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01093 CSPC PHARMA
RTNominal down5.770 -0.090 (-1.536%)
Others

24/06/2020 10:38

CSPC Pharma (01093) gets drug registration approval

[ET Net News Agency, 24 June 2020] CSPC Pharmaceutical Group Limited (01093) said
"Bortezomib for Injection (3.5mg)" developed by CSPC Ouyi Pharmaceutical Co., Ltd., a
subsidiary of the company, has obtained drug registration approval granted by the National
Medical Products Administration of the People's Republic of China, being the first generic
drug of this type deemed as passing the consistency of quality and efficacy evaluation in
China.
Bortezomib is the world's first oncology drug targeting the proteasome in targeted
therapy. (RC)

Back to Others

Remark: Real time quote last updated: 19/04/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.